The Role of GSK3 and its Reversal with GSK3 Antagonism in Everolimus Resistance

Pancreatic neuroendocrine tumors (panNETs) are often inoperable at diagnosis. The mTORC1 inhibitor everolimus has been approved for the treatment of advanced NETs. However, the regular development of resistance to everolimus limits its clinical efficacy. We established two independent everolimus-res...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Endocr Relat Cancer
Autori principali: Prada, Elke Tatjana Aristizabal, Spöttl, Gerald, Maurer, Julian, Lauseker, Michael, Koziolek, Eva Jolanthe, Schrader, Jörg, Grossman, Ashley, Pacak, Karel, Beuschlein, Felix, Auernhammer, Christoph Joseph, Nölting, Svenja
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7439002/
https://ncbi.nlm.nih.gov/pubmed/29895527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-18-0159
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi